Yazar "Eren, Necmi" seçeneğine göre listele
Listeleniyor 1 - 12 / 12
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Characteristics and outcomes of hospitalised older patients with chronic kidney disease and COVID-19: A multicenter nationwide controlled study(John Wiley & Sons Ltd, 2021) Özturk, Savaş; Turgutalp, Kenan; Arıcı, Mustafa; Gök, Mahmut; İslam, Mahmud; Altıparmak, Mehmet Rıza; Aydın, Zeki; Döner, Barıs; Eren, Necmi; Şengül, Erkan; Karadağ, Serhat; Özler, Tuba Elif; Dheir, Hamad; Pembegül, İrem; Taymez, Dilek Güven; Şahin, Garip; Dolarslan, Murside Esra; Soypaçacı, Zeki; Hür, Ender; Kara, Ekrem; Baştürk, Taner; Öğütmen, Melike Betül; Görgülü, Numan; Şahin, İdris; Ayli, Mehmet Deniz; Tuğlular, Zübeyde Serhan; Şahin, Gülizar; Tokgöz, Bülent; Tonbul, Halil Zeki; Yıldız, Alaattin; Sezer, Siren; Odabaş, Ali Rıza; Ateş, Kenan; Bakırdöğen, SerkanObjective Older adults with co-morbidities have been reported to be at higher risk for adverse outcomes of coronavirus disease 2019 (COVID-19). The characteristics of COVID-19 in older patients and its clinical outcomes in different kidney disease groups are not well known. Methods Data were retrieved from a national multicentric database supported by Turkish Society of Nephrology, which consists of retrospectively collected data between 17 April 2020 and 31 December 2020. Hospitalised patients aged 18 years or older with confirmed COVID-19 diagnosis suffering from stage 3-5 chronic kidney disease (CKD) or on maintenance haemodialysis (HD) treatment were included in the database. Non-uraemic hospitalised patients with COVID-19 were also included as the control group. Results We included 879 patients [388 (44.1%) female, median age: 63 (IQR: 50-73) years]. The percentage of older patients in the CKD group was 68.8% (n = 188/273), in the HD group was 49.0% (n = 150/306) and in the control group was 30.4% (n = 70/300). Co-morbidities were higher in the CKD and HD groups. The rate of presentation with severe-critical disease was higher in the older CKD and HD groups (43.6%, 55.3% and 16.1%, respectively). Among older patients, the intensive care unit (ICU) admission rate was significantly higher in the CKD and HD groups than in the control group (38.8%, 37.3% and 15.7%, respectively). In-hospital mortality or death and/or ICU admission rates in the older group were significantly higher in the CKD (29.3% and 39.4%) and HD groups (26.7% and 30.1%) compared with the control group (8.6% and 17.1%). In the multivariate analysis, in-hospital mortality rates in CKD and HD groups were higher than control group [hazard ratio (HR): 4.33 (95% confidence interval [CI]: 1.53-12.26) and HR: 3.09 (95% CI: 1.04-9.17), respectively]. Conclusion Among older COVID-19 patients, in-hospital mortality is significantly higher in those with stage 3-5 CKD and on maintenance HD than older patients without CKD regardless of demographic characteristics, co-morbidities, clinical and laboratory data on admission.Öğe Comparison of Therapeutic Plasma Exchange and Double FiltrationPlasmapheresis: Five Year Experience of Nephrology Unit(2021) Berk, Sibel Gökçay; Bakırdöğen, Serkan; Eren, Necmi; Hazanay, Yusuf; Gönüllü, Betül KalenderObjective: The aim of the study was to evaluate the outcomes and characteristics of therapeutic plasma exchange (TPE) and double filtration plasmapheresis (DFPP) in one center. Method: The data of cases treated with therapeutic plasmapheresis at the university hospital between 2007 and 2012 were retrospectively analyzed. 445 TPE and 391 DFPP sessions were done totally. Results: In the 5.5 years, in 116 cases 445 TPE and 391 DFPP sessions were done. The mean age was 46.61±16.83 years. There were 49 female and 67 male patients. Guillain-Barre syndrome ( 8.6%) was the commonly encountered indication for neurological diseases, glomerulonephritis ( 25%) was the leading indication for the renal-related diseases. Skin involvement due to diabetes mellitus (13.8%) and Pemphigus Vulgaris (5.2%) were the dermatological diseases. Complication rates were similar between DFPP and TPE sessions (p= 0.411). Conclusion: TPE and DFPP are safe and vital membrane separation techniques used as a treatment for a wide spectrum of diseases. These treatments can be safely done in hemodialysis units intensive care units and DFPP should be considered for the therapy refractory neurological diseases.Öğe Epicardial Adipose Tissue Thickness in Hemodialysis Patients(Wiley, 2014) Altun, Burak; Tasolar, Hakan; Eren, Necmi; Binnetoglu, Emine; Altun, Mehzat; Temiz, Ahmet; Gazi, EmineAim: Hemodialysis (HD) patients had higher cardiovascular mortality and it is related to atherosclerosis. Epicardial adipose tissue (EAT) thickness is a marker of atherosclerosis and independent predictor of coronary artery disease. The aim of our study was to evaluate the relationship between EAT and carotid intima-media thickness (CIMT) predictors of early atherosclerosis in HD patients. Methods: The study included 62 HD patients and 40 healthy controls. EAT thickness and CIMT were measured by echocardiography in all subjects. Results: Epicardial adipose tissue thickness and CIMT were higher (6.98 +/- 1.67 vs. 3.84 +/- 0.73 mm, P < 0.001, 0.94 +/- 0.17 vs. 0.63 +/- 0.11 mm, P < 0.001, respectively) in HD patients than in control subjects. EAT thickness were correlated with CIMT, HD duration, age, and calcium. In addition, HD duration, CIMT, and age were independent predictors of EAT thickness on HD patients in regression analysis. Conclusion: Epicardial adipose tissue thickness may be a useful indicator of early atherosclerosis in HD patients.Öğe Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-COVID-19 Period: A National Multicenter Case-Control Study from Turkey(S. Karger AG, 2023) Ozturk, Savas; Gursu, Meltem; Arici, Mustafa; Sahin, Idris; Eren, Necmi; Yilmaz, Murvet; Koyuncu, SumeyraIntroduction: There are not enough data on the post-CO-VID-19 period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data of PD patients after COVID-19 with a control PD group. Methods: This study, supported by the Turkish Society of Nephrology, is a national, multicenter retrospective case-control study involving adult PD patients with confirmed COVID-19, using data collected from April 21, 2021, to June 11, 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but without COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. Results: A total of 223 patients (COVID-19 group: 113, control group: 110) from 27 centers were included. The duration of PD in both groups was similar (median [IQR]: 3.0 [1.88-6.0] years and 3.0 [2.0-5.6]), but the patient age in the COVID-19 group was lower than that in the control group (50 [IQR: 40-57] years and 56 [IQR: 46-64] years, p < 0.001). PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure, and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at day 90. Only 1 (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition, and hypervolemia were significantly higher at day 90 in the COVID-19 group. Conclusion: Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 was not different from the control PD group. However, some patients continued to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia. © 2023 S. Karger AG. All rights reserved.Öğe Evalulation of Optical Coherence Tomography Measurements inPeritoneal Dialysis Patients(2021) Bek, Sibel; Batman, Adnan; Eren, Necmi; Tuğan, Büşra Yılmaz; Bakırdöğen, SerkanINTRODUCTION: Optical coherence tomography (OCT) is anon-invasive ocular imaging technique widely used nowadays.There are limited studies focusing on the OCT findings in PDpatients. Our aim is to compare retinal changes of peritonealdialysis (PD) patients with healthy control group by using OCT and investigate the effects of age, gender and duration of PDon these parameters. METHODS: In this cross-sectional study right and left eyes of32 patients and twenty right and left eyes of ten healthycontrols were included. Detailed ophthalmologicalexaminations with central macular thickness (CMT),peripapillary retinal nerve fiber layer (RNFL) thickness, andchoroidal thickness (using EDI-OCT) were measured. Macularthickness was measured at five different areas:central,superior, temporal, inferior and nasal. Theperipapillary RNFL thickness was analysed in six differentareas: temporal, inferotemporal, inferonasal, nasal,superonasal and superotemporal. RESULTS: Sixty-four eyes of 32 patients (18 males, 14females; aged 20 to 60 years, mean 48.67±12.25 years) with amean duration of PD of 46.80 months were included. Therewas a significant difference of macular thickness in the central,temporal, nasal, inferior and superior quadrants betweencontrols and PD patients (p < 0.05). Vitamin D3supplementation was linked to decreased macular thickness incentral, temporal, superior, nasal and inferior quadrants(p<0.05). There was a positive correlation between macularthickness in central and temporal quadrants with residualrenal function (p=0.006, p=0.019). DISCUSSION AND CONCLUSION: OCT revealed asignificant reduction of macular thickness in all quadrants inPD patients.Öğe HEPCIDIN AND VITAMIN D LEVELS: MUTUAL EFFECTS IN ANEMIA OF CHRONIC KIDNEY DISEASE(2021) Ustuner, Berna; Bek, Sibel Gökçay; Eren, Necmi; Bakirdogen, Serkan; Kalender, Betül GönüllüObjective: Hepcidin is a peptide with anti-microbial properties that is largely synthesized in the liver and has important roles in iron homeostasis,with serum levels elevated in chronic inflammatory conditions, including chronic kidney disease (CKD). Our aim was to discuss on the role ofvitamin D in regulation of hepcidin and anemia of CKD.Methods: The study group included 103 patients with CKD and 59 healthy individuals. The serum concentration of hepcidin was measured usingELISA, and the association to the following factors was evaluated: age, sex, body mass index, renal functions (estimated glomerular filtration rate,eGFR), drug history, serum biochemistry, complete blood count, iron and total iron binding capacity, ferritin, vitamin D, high sensitive C-reactiveprotein, C-reactive protein, and the erythrocyte sedimentation rate.Results: The mean age of the CKD group was 58.63 ± 11.8 years (with 16, 26, 27, 19, and 15 patients; respectively in each chronic kidney diseasestage, from I through V and nine on haemodialysis, six on peritoneal dialysis). The mean hepcidin concentration was higher in the chronic kidneydisease (30.3±24.7 ng/ml) than control (17.8 ± 8.4ng/ml) group (p<0.05). There was a positive association between hepcidin and CRP, ESR and thefollowing serum factors (urea, creatinine, ferritin, phosphate, pH, parathyroid hormone and alkaline phosphatase), with a negative association witheGFR, haemoglobin, haematocrit, calcium, magnesium, 25-OH vitamin D and bicarbonate levels.Conclusion: Hepcidin levels were found negatively correlated with 25-OH vitamin D levels which was related with the inflammatory effects ofvitamin D and hepcidin.Öğe Pregnancy and its outcomes in hemodialysis patients in Turkey(2022) Dheır, Hamad; Güngör, Özkan; Ulu, Memnune Sena; Oguz, Ebru Gok; Eren, Necmi; Altunören, Orçun; Tatar, ErhanBackground/aim: This study aimed to investigate pregnancy frequency and evaluate the factors affecting live births in hemodialysis\r(HD) patients. \rMaterials and methods: Female HD patients whose pregnancy was retrospectively reported between January 1, 2014, and December 31, 2019. The duration of HD, primary disease, and the information on whether the pregnancy resulted in abortion, stillbirth, or live birth, whether the HD duration was prolonged after diagnosing the pregnancy and whether it accompanied preeclampsia were recorded.\rResults: In this study, we reached 9038 HD female patients’ data in the study. A total of 235 pregnancies were detected in 145 patients.\rThe mean age was 35.42 (35 ± 7.4) years. The mean age at first gestation was 30.8 ± 6.5 years. The average birth week was 32 (28 –36) weeks. A total of 53.8% (no = 78) of the patients had live birth, 51.7% (no = 70) had at least one abortion in the first 20 weeks, and 13.1% (no = 19) had at least one stillbirth after 20 weeks. The rate of patients’ increased numbers of dialysis sessions during pregnancy was 71.7%. The abortion rate was 22.4% in those with increased HD sessions, whereas 79.3% in those not increased HD sessions (p < 0.001).\rLive birth frequency was 67.2% in the increased HD sessions group and 3.4% in those who did not differ in HD sessions (p < 0.001).\rConclusion: For the first time, we reported pregnancy outcomes in HD female patients, covering all regions of Turkey. It has been observed that; increasing the number of HD sessions in dialysis patients will decrease fetal and maternal complications and increase live birth rates.Öğe Rh (D) alloimmunization treated by double filtration plasmapheresis(Pergamon-Elsevier Science Ltd, 2019) Bek, Sibel Gokcay; Eren, Necmi; Uzay, Ant; Bakirdogen, SerkanHere in this report a 31 year old pregnant woman with positive serum antiglobulin test against anti-D antierythrocyte antibodies who was treated succesfully with double filtration plasmapheresis (DFPP) is presented. The DFPP was started in the early stage of pregnancy together with intravenous immunoglobulin therapy and the antierythrocyte antibody titer of the patient was successfully maintained in a stable level below 1:64 dilution. She delivered successfully on the 30th week of gestation. The favorable outcome of this patient implies that DFPP is an effective and safe treatment modality in pregnant women with red cell all oimmunization.Öğe The Association Between Serum Uric Acid and 25-Hydroxyvitamin D in Peritoneal Dialysis Patients(Turk Nefroloji Diyaliz Transplantasyon Dergisi, 2018) Bakirdogen, Serkan; Eren, Necmi; Bek, Sibel Gokcay; Yavuz, Sara; Tuncay, MehmetOBJECTIVE: In peritoneal dialysis (PD) patients, a low level of serum 25-hydroxyvitamin D is associated with an increased risk of cardiovascular events. Hyperuricemia is also associated with an increased mortality rate in chronic kidney disease patients. The aim of our study was to determine whether there was a relationship between serum uric acid and 25-hydroxyvitamin D in PD patients. MATERIAL and METHODS: A total of 48 PD patients were included in the study. Uric acid and 25-hydroxyvitamin D were determined simultaneously in each patient's serum. Mean serum uric acid and 25-hydroxyvitamin D levels of the patients were compared with each other. The cases where the P-value was below 0.05 were considered statistically significant. RESULTS: There was a statistically significant positive correlation between mean serum uric acid and 25-hydroxyvitamin D levels in PD patients (p=0.003; r=0.427). CONCLUSION: Serum uric acid and 25-hydroxyvitamin D levels in peritoneal dialysis patients may be indicative of dietary incompatibility. Prospective studies involving more patients are needed in PD patients to prove a relationship between these two serum markers.Öğe The Effect of Erythropoiesis-Stimulating Agents on Platelet Aggregation in Peritoneal Dialysis Patients(Istanbul Training & Research Hospital, 2019) Bakirdogen, Serkan; Eren, Necmi; Bek, Sibel Gokcay; Yavuz, SaraIntroduction: Erythropoietin (Epo) is a hormone that is synthesized in the kidneys and that stimulates the erythropoiesis in the bone marrow. Epo has effects apart from the erythropoiesis. In chronic renal failure (CRF) patients, hemorrhagic diathesis is observed, and Epo production is decreased. Erythropoiesis-stimulating agents (ESAs) are widely used in the treatment of renal anemia in these patients. Our study aimed to investigate the effect of ESA5 use on platelet aggregation in peritoneal dialysis (PD) patients due to CRF. Methods: Forty-three PD patients were included in the study. Seventeen patients had been using ESAs for anemia for at least three months (ESAs user group). Twenty-six patients were not using ESAs since they did not have indications (non-ESAs user group). Platelet aggregation measurement from the whole blood was carried out in each patient by a multiplate device. The calculated values [area under the curve (AUC), aggregation, and velocity] were recorded. The results were evaluated statistically, and p<0.05 was accepted as statistically significant. Results: In the non-ESAs user group, the mean hemoglobin level was found higher when compared to the other group, and this difference was statistically significant (p<0.001). The percentage of transferrin saturation was found higher in the ESAs user group (p=0.021). It was observed that AUC, aggregation, and velocity values were lower in the ESA5 user group, and the result was not statistically significant (p values were 0.202, 0.329, 0.290, respectively). Conclusion: ESAs use in PD patients did not have any effect on platelet aggregation. Further prospective studies involving platelet aggregation tests before and after ESA treatment in dialysis patients are needed.Öğe The Effects of Peripheral Platelet and Leukocyte Counts on Platelet Agregation in Peritoneal Dialysis Patients(2018) Bakırdöğen, Serkan; Bek, Sibel Gökçay; Eren, Necmi; Uzay, Ant; Bilgili, Ümit; Çekmen, Mustafa Baki; Yavuz, SaraINTRODUCTION: Studies in healthy individuals andpatients with coronary artery disease have demonstratedthat circulating platelet and leukocyte counts affect plateletaggregation. The aim of our study was to investigatewhether there is such a relationship betweenleukocyte/platelet counts and platelet aggregation in endstagerenal disease patients on peritoneal dialysis (PD).METHODS: Forty-three PD patients were included in thestudy. Multiple electrode aggregometry method capable ofmeasuring platelet aggregation in whole blood was used.RESULTS: A statistically significant positive correlationbetween platelet aggregation and leukocyte and platelet countsin complete blood count (CBC) was seen. This positivecorrelation was stronger for platelets than leukocytes.DISCUSSION and CONCLUSION: Platelet and leukocytecounts in CBC in PD patients might be important on plateletaggregation. This might be another risk factor contributing toalready increased thrombosis risk in these patients.Öğe The effects of serum leptin levels on thrombocyte aggregation in peritoneal dialysis patients(Professional Medical Publications, 2016) Bakirdogen, Serkan; Eren, Necmi; Bek, Sibel Gokcay; Mehtap, Ozgur; Cekmen, Mustafa BakiObjective: Serum leptin levels of chronic kidney disease patients have been detected higher than normal population. The aim of this study was to investigate the effects of serum leptin levels on thrombocyte aggregation in peritoneal dialysis patients. Methods: Fourty three peritoneal dialysis patients were included in the study. Thrombocyte aggregation was calculated from the whole blood subsequently the effects of different concentrations of human recombinant leptin on thrombocyte aggregations were investigated. Four test cells were used for this process. While leptin was not added into the first test cell, increasing amounts of leptin was added into the second, third and fourth test cells to attain the concentrations of 25, 50 and 100 ng/ml respectively. Results: Thrombocyte aggregation was inhibited by recombinant leptin in peritoneal dialysis patients. Thrombocyte aggregation mean values were found statistically significantly higher in first test cell when compared to leptin groups in peritoneal dialysis patients. For leptin groups we could not find any statistically significant differences for thrombocyte aggregation mean values between any of the groups. Conclusion: Further studies with larger number of peritoneal dialysis patients are required to prove the action of leptin on thrombocyte aggregation.
